Published in Hepatology on June 26, 2011
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52
Modulation of cardiac fibrosis by Krüppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes. Cardiovasc Res (2015) 1.43
Krüppel-like factors in cancer. Nat Rev Cancer (2013) 1.32
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma. J Hepatol (2014) 1.09
MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res (2014) 1.09
MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget (2015) 1.05
Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform. RNA Biol (2014) 0.87
Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology (2012) 0.85
Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol (2016) 0.81
Oxidative stress modulates KLF6Full and its splice variants. Alcohol Clin Exp Res (2012) 0.79
Transcript profiling identifies iqgap2(-/-) mouse as a model for advanced human hepatocellular carcinoma. PLoS One (2013) 0.79
A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination. Oncogene (2016) 0.79
Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research. Quant Imaging Med Surg (2015) 0.77
Ah Receptor Pathway Intricacies; Signaling Through Diverse Protein Partners and DNA-Motifs. Toxicol Res (Camb) (2015) 0.77
KLF6 inhibited oral cancer migration and invasion via downregulation of mesenchymal markers and inhibition of MMP-9 activities. Int J Med Sci (2017) 0.75
Selecting Optimal Combinations of Transcription Factors to Promote Axon Regeneration: Why Mechanisms Matter. Neurosci Lett (2016) 0.75
Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury. Sci Rep (2017) 0.75
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Krüppel-like factors: three fingers in many pies. J Biol Chem (2001) 5.05
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (2001) 3.22
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene (1993) 3.08
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
NF-kappaB and cancer: mechanisms and targets. Mol Carcinog (2006) 2.40
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Genetics of hepatocellular carcinoma. Semin Cancer Biol (2000) 2.30
A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res (1995) 2.23
The p53 and Mdm2 families in cancer. Curr Opin Genet Dev (2002) 2.07
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res (2005) 1.65
P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer (2000) 1.63
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res (2004) 1.57
Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res (2006) 1.51
Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene (1995) 1.44
Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer (2006) 1.30
A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function. Oncogene (2004) 1.20
Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol (2009) 1.20
Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer (2007) 1.17
An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis (2004) 1.15
Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene (1993) 1.12
In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene (2007) 1.12
Oscillations by the p53-Mdm2 feedback loop. Adv Exp Med Biol (2008) 1.07
Premalignant lesions of hepatocellular carcinoma: pathologic viewpoint. J Hepatobiliary Pancreat Surg (2000) 1.06
Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. Clin Cancer Res (2003) 1.05
PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann Hepatol (2008) 1.05
Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility. BMC Genomics (2008) 0.97
p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene (1994) 0.95
Mdm2: p53's lifesaver? Mol Cell (2007) 0.89
Hepatocellular carcinoma. Lancet (2012) 18.09
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
The first 30 years of p53: growing ever more complex. Nat Rev Cancer (2009) 8.00
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol (2003) 4.46
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Global and local architecture of the mammalian microRNA-transcription factor regulatory network. PLoS Comput Biol (2007) 4.31
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. Mol Cell (2006) 3.98
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat Cell Biol (2008) 3.08
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol (2011) 2.82
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Living with p53, dying of p53. Cell (2007) 2.62
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53
Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene (2002) 2.50
Activation of hepatic stellate cells--a key issue in liver fibrosis. Front Biosci (2002) 2.49
The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev (2008) 2.48
Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell (2008) 2.46
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev (2006) 2.41
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer (2009) 2.38
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell (2007) 2.32
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene (2002) 2.27
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer (2011) 2.18
The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell (2004) 2.16
Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks. Mol Cell (2011) 2.16
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology (2012) 2.11
Major achievements in hepatocellular carcinoma. Lancet (2009) 2.10
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
The p53 and Mdm2 families in cancer. Curr Opin Genet Dev (2002) 2.07
Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology (2003) 2.06